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Proforma 
 
A Study on Lipid profile in CKD 
 
Name of the patient : 
Age / Sex : 
IP/OP No : 
Address : 
Height (cms) :    Weight (kgs) :    BMI : 
 
Diagnosis : 
 
Chief Complaints : 
 
Past History of 
1.  DM     :  Yes/No 
2.  Coronary heart disease  :  Yes/No 
3.  Hypertension   :  Yes/No 
4.  Thyroid Disease   :  Yes/No 
5.  Drug intake (Steriods, Anti thyroid drugs,  :  Yes/No 
 Estrogen/OCP, B-blockers) 
6.  PD  :  Yes/No 
7.  HD  :  Yes/No 
 
Personal History of 
1.  Smoking : 
2. Alcoholism : 
 
General Examination 
PR (per min) : 
BP ( mm Hg) : 
Xanthomas/Xanthelesma : 
Arcus senilis : 
 
Systemic Examination 
CVS : 
RS : 
Abdomen : 
CNS : 
 
Investigations 
Blood sugar(mg/dL) : FBS- PPBS- 
HbA1c- sr.albumin- 
Urea (mg/dL) : 
Creatinine (mg/dL) : 
Sodium(mEql/L) : Potassium (mEql/L) : 
24 hrs urine protein:                         Urine P/Cr: 
Creatinine clearance : 
(ml/min) 
Lipid profile(mg/dL) 
TC : TGL : HDL 
LDL  
TSH 
Urine 
ECG: 
USG abdomen : 
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INTRODUCTION 
 
   Cardiovascular disease (CVD) is a major cause of mortality in 
patients with mild to moderate chronic kidney disease (CKD) and end-
stage renal disease (ESRD) 1, 2 
 
Cardiovascular mortality 500 times higher in 25- to 34-year-old 
ESRD patients than in individuals from the general population of the same 
age and race. 2, 3 
 
  Primary care physicians (PCP) often manage patients with CKD in 
the early stages of the disease and have a pivotal role in affecting long-
term outcomes in CKD patients related to cardiovascular and all-cause 
mortality. 7 
 
  In a retrospective cohort study only a tiny minority of patients (0.5–
1%) with mild to moderate CKD developed ESRD over a 5-year follow-
up,while as many as 19 and 24% of these patients with mild and moderate 
renal insufficiency, respectively, died mostly of cardiovascular 
complications in the same period4 . 
2 
  Hyperlipidemia, one of the important risk factor of atherosclerosis, 
is an abnormality commonly encountered in patients with chronic kidney 
disease. 
 
  Other risk factor includes hypertension, diabetes mellitus, smoking, 
and obesity. 
 
Indian studies on lipid profile abnormalities in chronic renal failure 
(CRF) have varied from no abnormalities at all to significant abnormality 
(Hypertriglyceridemia and reduced HDL) as described in the Western 
literature. 
 
  The study by B Shah, S Nair, demonstrates that CRF is commonly 
accompanied by lipid abnormality in the form of Hypertriglyceridemia. 5 
 
The study by Sumathi M.E, Manjunath M Tempad showed serum 
TGL, TC, HDL-C, have significantly increased in conservatively managed 
patients than in Haemodialysis patients. 6 
 
 The present study is undertaken to explore the altered lipid, 
lipoprotein abnormalities in CKD from stage III to stage V classified as per 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
3 
(NKFK/DOQI) guidelines, which plays a vital role in development of 
atherosclerotic cardiovascular disease. 
 
   There is also associated thyroid dysfunction seen in CKD patients.  
 
  A few reports have appeared from India, where various parameters 
of thyroid function were measured in patients with CRF. In order to gain 
further insight, this study included measuring the Thyroid Stimulating 
Hormone (TSH) levels. 
4 
AIMS and OBJECTIVES OF THE STUDY 
 
1.  To identify lipid pattern in chronic kidney disease patients. 
 
2.  To analyze lipid alterations that can occur in Chronic Kidney 
Disease patients. 
 
3.  To study the correlation between renal function and lipid 
abnormalities in Chronic Kidney Disease. 
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REVIEW OF LITERATURE 
 
Definition of Chronic Kidney disease 
 The Kidney Disease Outcomes Quality Initiative (K/DOQI) of 
the National Kidney Foundation (NKF) defines chronic kidney disease as 
either kidney damage or a decreased glomerular filtration rate (GFR) of 
less than 60 ml/min/1.73 m2 for 3 or more months.8 
 
1.  Kidney damage for >3 months is defined by structural or 
functional   abnormalities of the kidney with or without 
reduction in GFR manifest either by 
 A.  pathological abnormalities or 
B.  Markers of kidney damage including abnormalities of 
composition of blood or urine or abnormalities in imaging 
tests. 
 
2.  GFR <60ml/min/1.73m2  for >3 months with or without kidney 
damage. 
 
Epidemiology of CKD in India 
The epidemiology of CKD in India is very different from the West. 
Patients are roughly two decades younger, and a substantial proportion 
6 
present with small kidneys. In the absence of nationwide reporting systems 
or registries, the true incidence and prevalence is difficult to determine.  
 
 The socioeconomic implications of a young population afflicted 
with a potentially terminal illness are devastating and in the face of 
growing epidemics of diabetes and hypertension, the burden of CKD is not 
likely to ease.9 
 
Combining all the available literature, both published and 
unpublished, from various sources, it will not be unwise to comment that 
the yearly incidence of ESRD in India is approximately 150–200 pmp and 
diabetes is also an important cause of CKD in approximately 30–40% of 
the patients. 10 
 
ETIOLOGY 
Diabetes has emerged as the most frequent cause (30–40%) 
followed by hypertension (14–22%), CGN (16–20%), CIN (5.4–
12.7%),heredofamilial disease (8.4%) and obstruction including calculus 
(2.9%).11  
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Other causes include Primary glomerular diseases like Membranous 
nephropathy, IgA nephropathy, Focal and segmental glomerulosclerosis 
(FSGS) and Membranoproliferative glomerulonephritis. 
 
Vascular causes are renal artery stenosis, vasculitis, atheroemboli 
and Hypertensive nephrosclerosis. 
 
The Causes for tubulointerstitial disease includes Drugs (e.g., sulfa, 
allopurinol), Infection (viral, bacterial, parasitic), Heavy metals and 
Radiation nephritis. 
 
Pathophysiology of Chronic Kidney Disease 12 
This is categorized by two broad sets of mechanisms of damage 
1.  Initiating mechanisms specific to the underlying aetiology 
(genetically determined abnormalities in kidney development or 
integrity, immune complex deposition and inflammation in certain 
types of glomerulonephritis).  
2.  A set of progressive mechanisms, involving hyper filtration and 
hypertrophy of the remaining viable nephrons.  
 
The responses to reduction in nephron number are mediated by 
vasoactive hormones, cytokines, and growth factors.  Increased intra renal 
8 
activity of the renin-angiotensin axis appears to contribute both to the 
initial adaptive hyper filtration and to the subsequent maladaptive 
hypertrophy and sclerosis, the latter, in part, owing to the stimulation of 
transforming growth factor (TGF). 
 
Pathophysiology and Biochemistry of Uremia 
Accumulation serum urea and creatinine do not account for the 
many symptoms and signs but hundreds of toxins that accumulate in renal 
failure have been implicated in the uremic syndrome. These include water-
soluble, hydrophobic, protein-bound, charged, and uncharged compounds. 
Additional categories of nitrogenous excretory products include guanidino 
compounds, urates and hippurates, products of nucleic acid metabolism, 
polyamines, myoinositol, phenols, benzoates, and indoles. 
 
A host of metabolic and endocrine functions normally performed by 
the kidneys is also impaired or suppressed, and this results in anaemia, 
malnutrition, and abnormal metabolism of carbohydrates, fats, and 
proteins. 
 
  Plasma levels of many hormones, including PTH, FGF-23, insulin, 
glucagon, steroid hormones including vitamin D and sex hormones, and 
prolactin, change with renal failure. The inflammation associated with 
9 
renal impairment is important in the malnutrition-inflammation-
atherosclerosis/calcification syndrome, which contributes in turn to the 
acceleration of vascular disease. 
 
STAGES of   GFR 
aWith risk factors for CKD bwith demonstrated kidney damage (e.g., 
persistent proteinuria, abnormal urine sediment, abnormal blood and urine 
chemistry, abnormal imaging studies) 
 
In stage 1 and stage 2 chronic kidney diseases, GFR alone does not 
clinch the diagnosis. Other markers of kidney damage, including 
abnormalities in the composition of blood or urine or abnormalities on 
imaging studies, should also be present in establishing a diagnosis of stage 
1 and stage 2 chronic kidney disease. 
 
The plasma creatinine value will approximately double with a 50% 
reduction in GFR. A rise in plasma creatinine from a baseline value of 0.6 
Stage GFR, mL/min per 1.73 m
2 
 
0 
1 
2 
3 
4 
5 
>90a 
90b 
60–89 
30–59 
15–29 
<15 
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mg/dl to 1.2 mg/dl in a patient, although still within the reference range, 
actually represents a loss of 50% of functioning nephron mass. (12) 
 
CLINICAL FEATURESAND LABORATORY ABNORMALITES 
Fluid and electrolyte disturbances 
• Volume expansion, 
• Hyponatremia, 
• Hyperkalemia, 
• Hyperphosphatemia. 
 
Endocrine - Metabolic disturbances 
• Secondary hyperparathyroidism, 
• Adynamic bone disease, 
• Vit. D deficient osteomalacia, 
• Carbohydrate resistance, 
• Hyperuricemia, 
• Hypertriglyceridemia, Increased Lp (a) levels, 
• Decreased HDL level Malnutrition, 
• Amenorrhea, infertility, 
• Sexual dysfunction, 
• β2 micro globulin associated amyloidosis. 
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Neuromuscular Disturbances 
• Fatigue, 
• Sleep disorders, 
• Headache, 
• Impaired mentation, 
• Lethargy, 
• Asterixis, 
• Muscular rigidity, 
• Peripheral neuropathy, 
• Restless leg syndrome, 
• Myoclonus, Seizures, Coma, 
• Muscle cramps, Myopathy, 
• Dialysis disequilibrium syndrome. 
 
Cardiovascular and pulmonary complication 
• Arterial hypertension, 
• Congestive heart failure or pulmonary edema, 
• Pericarditis, 
• Hypertrophic or dilated cardiomyopathy, 
• Accelerated atherosclerosis, 
• Hypotension and arrhythmias, vascular calcification. 
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Dermatologic Disturbances 
• Pallor, 
• Hyper pigmentation, 
• Pruritus, 
• Ecchymoses, 
• Fibrosing dermopathy and Uremic frost. 
 
Gastro Intestinal disturbances 
• Anorexia, Nausea and vomiting, 
• Gastroenteritis, 
• Peptic ulcer, 
• Gastrointestinal bleeding, 
• Idiopathic ascites, 
• Peritonitis. 
 
Hematologic and Immunologic disturbances 
• Anaemia, 
• Lymphocytopenia, 
• Bleeding diathesis, 
• Increased susceptibility to infection, 
• Leukopenia, Thrombocytopenia. 
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INVESTIGATIONS 
Complete blood count (CBC), blood urea, serum creatinine, 
urinalysis, with calculation of renal function, urine PCR ratio, and 24hrs 
urine protein. 
 
Serum albumin levels may also be measured, as patients may have 
hypoalbuminemia due to urinary protein loss or malnutrition. 
 
A lipid profile should be performed in all patients with chronic 
kidney disease because of their increased risk of cardiovascular disease.  
 
Serum phosphate, 25 hydroxy vitamin D, alkaline phosphatase, and 
intact parathyroid hormone (PTH) level. 
 
Renal ultrasound and other imaging studies. 
 
Measurement of GFR 
1.  Equation from the Modification Diet in Renal Disease study 
MDRD Study equation provides a clinically useful estimate of GFR 
up to approximately 90 mL/min/1.73 m2 
Estimated GFR (mL/min per 1.73 m2) = 1.86 x (PCr)–1.154 x (age)–0. 203 
Multiply by 0.742 for women Multiply by 1.21 for African Americans 
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2.  Cockcroft-Gault equation 
 Estimated creatinine clearance (mL/min) 
  (140–age) x body weight (kg) 
  =  ––––––––––––––––––––––––– 
  72 x PCr (mg/dL) 
 Multiply by 0.85 for women 
 
The CKD-EPI Creatinine Equation 
The CKD-EPI creatinine equation is based on the same four 
variables as the MDRD Study equation, but uses a 2-slope “spline” to 
model the relationship between estimated GFR and serum creatinine, and a 
different relationship for age, sex and race. The equation was reported to 
perform better and with less bias than the MDRD Study equation, 
especially in patients with higher GFR.  
 
 GFR  =  141 x min (scr/κ,1 )α  x max (scr/κ, 1 )-1.209 x  
    0.993 Age  x 1.018 (if female) X 1.159 (if  black ) 
 
(The National Kidney Foundation  K/DOQI Clinical Practice Guidelines 
for Estimation of Glomerular Filtration Rate)13 
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TREATMENT  
Fluid, Electrolyte, Acid-Base Disorders 
Adjustments in the dietary intake of salt and use of loop diuretics, 
with metolazone. 
 
Water restriction is indicated only if there is a problem with 
hyponatremia.Intractable ECF Volume expansion, despite dietary salt 
restriction and diuretic therapy, may be an indication to start renal 
replacement therapy. 
 
 Hyperkalemia needs dietary restriction of potassium, avoidance of 
potassium supplements and ACE inhibitors or ARB.  While potassium-
binding resins, can promote potassium loss through the GI tract and may 
reduce the incidence of hyperkalemia in CKD patients. 
 
 Intractable hyperkalemia is an indication to consider institution of 
dialysis in a CKD patient. The renal tubular acidosis and subsequent anion-
gap metabolic acidosis in progressive CKD will respond to alkali 
supplementation, typically with sodium bicarbonate will respond to 
sodium bicarbonate. 
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 Management of Hypertension 
In CKD patients with diabetes or proteinuria >1 g per 24 h, blood 
pressure should be reduced to 125/75 
-  Salt restriction  
-  ACE inhibitors and ARBs, side effect of these are hyperkalemia. 
   Metolazone can improve potassium excretion in addition to 
improving blood pressure control. 
 
Management of Cardiovascular Disease 
 Lifestyle changes, including regular exercise and Hyperlipidemia in 
patients with CKD should be managed according to national guidelines. If 
dietary measures are not sufficient, preferred lipid-lowering medications, 
such as statins, should be used.  
 
Proteinuria –To reduce to <1g/24hr use an Angiotensin converting 
enzyme inhibitor or angiotensin receptor antagonist. 
 
 Glycemic control in DM - Hb AIC < 7% 
 
Smoking – cessation  
 
Severe ↓ GFR -Preparation for kidney replacement therapy. 
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DYSLIPIDEMIAS 
Dyslipidemia  has been established as a well-known traditional risk 
factor for CVD in the general population and large-scale observational 
studies have shown that total  and low-density lipoprotein (LDL)-
cholesterol values are two of the most important independent predictors of 
cardiovascular morbidity and mortality [14]. Recent meta-analyses of 
prospective studies indicate that elevated triglycerides are also an 
independent risk factor for CAD. Factors contributing to elevated 
triglycerides in the general population include: obesity, physical inactivity, 
cigarette smoking, excess alcohol intake, high carbohydrate diet, type 2 
diabetes, chronic renal failure, certain drugs like corticosteroids and 
estrogens. 
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 ATP III Classification of LDL, Total, and HDL Cholesterol(mg/dL)15)(15) 
 
LDL Cholesterol 
 <100mg/dL    Optimal 
100-129mg/dL  above optimal  
130-159mg/dL    Borderline high 
160-189mg/dL  High 
>190mg/dL   Very high 
 
Total Cholesterol 
<200mg/dL   Desirable 
200-239mg/dL  Borderline high 
>240mg/dL   High 
 
HDL Cholesterol 
<40mg/dL  Low 
>60mg/dL   High 
 
Triglycerides 
 <150 mg/dL    Normal triglycerides 
150-199 mg/dL  Borderline-high 
 200-499mg/dl   High  
 >500 mg/dL   very high 
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The Pathways of Lipid Transport 
  These pathways include the exogenous pathway, the endogenous 
pathway, and the pathway of reverse cholesterol transport. 
 
Exogenous Pathway 
  Dietary triglycerides are hydrolyzed by lipases within the intestinal 
lumen and emulsified with bile acids to form micelles. Cholesterol is 
esterified in the enterocyte to form cholesteryl esters Longer-chain fatty 
acids (>12 carbons) are incorporated into triglycerides and packaged with 
apoB-48, cholesteryl esters, retinyl esters, phospholipids, and cholesterol 
to form chylomicrons. Nascent chylomicrons are secreted into the 
intestinal lymph and delivered via the thoracic duct directly to the systemic 
circulation. The particles encounter lipoprotein lipase (LPL), in the 
endothelial surfaces of capillaries in adipose tissue, heart, and skeletal 
muscle The triglycerides of chylomicrons are hydrolyzed by LPL, and free 
fatty acids are released.  The released free fatty acids are taken up by 
adjacent myocytes or adipocytes and either oxidized to generate energy or 
reesterified and stored as triglyceride.  The chylomicron particle 
progressively shrinks in size creating chylomicron remnants.which are 
rapidly removed from the circulation by the liver through a process that 
requires apoE as a ligand for receptors in the liver.  
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Endogenous Pathway 
 The triglycerides of VLDL are derived predominantly from the 
esterification of  long-chain fatty acids in the liver. The packaging of 
hepatic triglycerides with the other major components of the nascent 
VLDL particle (apoB-100, cholesteryl esters, phospholipids, and vitamin 
E) requires the action of the enzyme microsomal triglyceride transfer 
protein (MTP). After secretion into the plasma, VLDL acquires multiple 
copies of apoE and apolipoproteins of the C series by transfer from HDL. 
As with chylomicrons, the triglycerides of VLDL are hydrolyzed by LPL, 
especially in muscle, heart, and adipose tissue. After the VLDL remnants 
dissociate from LPL, they are referred to as IDLs, which contain roughly 
similar amounts of cholesterol and triglyceride. The liver removes 
approximately 40–60% of IDL by LDL receptor–mediated endocytosis via 
binding to apoE .Lipoprotein(a) [Lp(a)] is a lipoprotein similar to LDL in 
Lipid and protein composition, but it contains an additional protein called 
apolipoprotein(a) [apo(a)]. Apo(a) is synthesized in the liver and attached 
to apoB-100 by a disulfide linkage. The major site of clearance of Lp(a) is 
the liver, but the uptake pathway is not known. 
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HDL Metabolism and Reverse Cholesterol Transport 
 Cholesterol in peripheral cells is transported from the plasma 
membranes of peripheral cells to the liver and intestine by a process 
termed "reverse cholesterol transport" that is facilitated by HDL. 
 
 HDL cholesterol is transported to hepatocytes by both an indirect 
and a direct pathway. HDL cholesteryl esters can be transferred to apoB-
containing lipoproteins in exchange for triglyceride by the cholesteryl ester 
transfer protein (CETP). The cholesteryl esters are then removed from the 
circulation by LDL receptor–mediated endocytosis. HDL cholesterol can 
also be taken up directly by hepatocytes via the scavenger receptor class 
B1 (SR-B1), a cell surface receptor that mediates the selective transfer of 
Lipids to cells. 
 
 HDL particles undergo extensive remodelling within the plasma 
compartment by a variety of Lipid transfer proteins and lipases. 
 
Dyslipidemia in CKD 
It Varies according to renal function and degree of proteinuria. As 
GFR falls TGL increase and HDL falls and  as proteinuria increases 
TC,TGL,LDL increases. Low HDL is an independent risk factor for CV 
events. 16  
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 According to ARIC(Atherosclerosis risk in communities) Study 
High TGL and low HDL increases the risk of declining kidney function. 17  
 
 Dyslipidemia, regardless of underlying cause (DM, HT), has a role 
in development of cardio vascular events and progression of CKD.18 
 
 According to ATP (Adult Treatment program) III for CAD in the 
management of CKD focuses on LDL as primary target.19 
 
 Sharma, et al 38 and Kunde et al 39 observed no hyperlipidemia in 
patients of CRF. On the other hand, Gupta 40 and Das et al 41 observed 
lipid abnormalities similar to those reported in Western studies i.e. 
Hypertriglyceridemia and reduced High density lipoprotein (HDL).  
 
Triglyceride abnormalities  
 Hypertriglyceridemia is partially due to a down regulation of 
lipoprotein lipase (LPL), hepatic lipase, very low-density lipoprotein 
(VLDL) and low-density lipoprotein receptor (LDL-r) expression 54 and as 
well as increased plasma apoC-III (a potent inhibitor of lipoprotein lipase) 
apoC-II (activator of lipoprotein lipase) ratio. 20  
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The down regulation of the expression of several genes 21–23 along 
with the changes in the composition of lipoprotein particles 24 and the 
direct inhibitory effect of various uremic ‘toxins’ on the enzymes involved 
in lipid metabolism25, represent the most important pathophysiological 
mechanisms underlying the development of Hypertriglyceridemia in renal 
failure. 21   
 
 CKD-induced hyperparathyroidism to the pathogenesis of 
lipoprotein lipase deficiency impaired HDL maturation, insulin resistance, 
reduced physical activity and diminished thyroxin to triiodothyronine 
conversion, which are common features of ESRD, contribute to diminished 
production and impaired activity of lipoprotein lipase. Recurrent 
heparinization in the course of haemodialysis procedure is thought to 
further contribute to lipoprotein lipase depletion in ESRD patients by 
promoting release and degradation of the tissue-bound stores of this 
molecule.26  
 
HDL Abnormalities in CKD 
The overall reduction in plasma HDL in the ESRD population which 
appears to be due to its diminished production [27]. The primary reason 
for impaired maturation of Cholesterol ester poor pre-HDL to mature 
cholesterol ester-rich HDL in advanced CKD is LCAT deficiency. Serum 
24 
LCAT activity and concentration are markedly reduced in ESRD patients 
28 which is due to its diminished production by the liver in CKD.29,30   
 
 In addition, hypoalbuminemia commonly seen in advanced CKD 
may, in part, contribute to reduced HDL cholesterol level.  
 
Reduction in HDL cholesterol in advanced CKD is coupled with 
elevated HDL triglyceride contents. This is primarily due to deficiency in 
hepatic triglyceride lipase. The reduction in HDL antioxidant and anti-
inflammatory properties in ESRD is most likely due to the prevailing 
Oxidative stress and inflammation as shown in other conditions.  
 
LDL cholesterol  
Elevated plasma LDL cholesterol concentration is common in 
nephrotic syndrome but is not a typical feature of patients with advanced 
CKD, especially those who are on HD. There are, however, qualitative 
changes in LDL in patients with CKD and dialysis patients. The 
proportions of sdLDL and IDL, which are considered to be highly 
atherogenic, are increased. sdLDL is a subtype of LDL that has high 
propensity to penetrate the vessel wall, becomes oxidized, and triggers the 
atherosclerotic process. LDL removed from the circulation, mainly by 
macrophages, through scavenger receptors. This leads to formation of 
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cholesterol-engorged foam cells, a crucial early step in atheromatous 
plaque formation Expression of both major scavenger receptors, SR-A and 
CD36, is increased in uremic patient. Furthermore, uptake of unmodified 
LDL by LDL receptors is enhanced in inflammation, a state that often 
accompanies CKD. This also leads to foam cell formation and is believed 
to constitute a risk factor for accelerated atherogenesis.  
 
Total cholesterol 
Plasma total cholesterol is usually normal or reduced and only 
occasionally elevated in patients with ESRD.  
 
It should be noted that heavy proteinuria leads to up regulation of 
HMG-CoA reductase Therefore, heavy proteinuria, when present, can 
modify HMG-CoA reductase expression and activity in humans causing 
hypercholesterolemia in ESRD patients maintained on peritoneal dialysis 
in whom CRF is compounded by substantial obligatory losses of proteins 
through the peritoneum.  
 
However, heavy proteinuria alone or in combination with chronic 
renal insufficiency results in acquired LDL receptor deficiency,  
which plays a central role in the genesis of the associated 
hypercholesterolemia.31, 32. 
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Lipoprotein [Lp(a)] 
 Lipoprotein [Lp(a)] is an LDL-like particle whose protein moiety 
contains apolipoprotein (a) [apo(a)] that is covalently bound to an LDL 
particle. Lp(a) concentrations are strongly genetically determined by the 
apo(a) gene. Individuals with high molecular weight or large apo(a) 
isoforms have on average low plasma Lp(a) concentrations, whereas those 
with low molecular weight or small isoforms usually exhibit high plasma 
Lp(a) concentrations. 
 
In kidney disease, plasma Lp(a) levels are also influenced by GFR. 
In patients with large apo(a) isoforms but not those with small apo(a) 
isoforms, plasma Lp(a) levels begin to increase in stage1 CKD before GFR 
starts to decrease 37 This isoform-specific increase in plasma Lp(a) levels 
was observed in several studies in non-nephrotic patients with CKD and 
HD patients 37 In contrast, in patients with nephrotic syndrome and PD 
patients, increases in plasma Lp(a) levels occur in all apo(a) isoform 
groups, probably as a consequence of the pronounced protein loss and a 
subsequently increased production in the liver.  The elevation of Lp(a) in 
CKD is an acquired abnormality, mostly influenced by the degree of 
proteinuria and less by the cause of kidney disease.33  
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Thus it has been shown that Lp(a) is an independent risk factor for 
CVD in both the general and the CKD population. Its levels are increased 
in CKD and especially in patients undergoing PD as a result of significant 
protein losses and subsequent apolipoprotein overproduction.  
 
Common features of serum lipid/lipoprotein profile in predialysis 
CKD patients with  treated with chronic haemodialysis or peritoneal 
dialysis 35 follows. 
Serum Lipid 
CKD Patients 
 
Hemodialysis 
Patients 
Peritoneal 
Dialysis 
Patients 
 
Heavy 
proteinuria 
Minimal 
proteinuria  
 
Triglycerides ↑ ↑ ↑ ↑  
Total 
cholesterol 
↑ ↔, ↓ ↔, ↓ Rarely ↑ Frequently ↑  
LDL 
cholesterol 
↑ ↔, ↓ or ↑ ↔, ↓ Rarely ↑ Frequently ↑  
Small dense 
LDL 
↑ ↑ ↑ ↑  
IDL 
cholesterol 
↑ ↑ ↑ ↑  
HDL 
cholesterol 
↓ ↓ ↓ ↓  
apoA-I, 
apoA-II 
↓ ↓ ↓ ↓  
apoC-III ↑ ↑ ↑ ↑  
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CONSEQUENCES OF DYSLIPIDEMIA  
Hyperlipidemia can potentially accelerate progression of renal 
disease by several mechanisms. First, reabsorption of fatty acids, 
phospholipids, and cholesterol contained in the filtered proteins (albumin 
and lipoproteins) by tubular epithelial cells can stimulate tubulointerstitial 
inflammation, foam cell formation, and tissue injury36 Second, 
accumulation of lipoproteins in glomerular mesangium can promote matrix 
production and glomerulosclerosis37,38. In addition, impaired HDL-
mediated reverse cholesterol transport can further contribute to tissue 
injury by limiting the unloading of the excess cellular cholesterol and 
phospholipid burden. 
 
The risk of cardiovascular morbidity and mortality is profoundly 
increased in patients with CKD. For instance, the majority of patients with 
CKD die of cardiovascular events before reaching ESRD.  
 
  Accumulation of oxidation-prone atherogenic lipoprotein remnants 
and impaired HDL-mediated reverse cholesterol transport, which are the 
defining features of uremic dyslipidemia, may play a major part in the 
pathogenesis of atherosclerosis in this population.  
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Thyroid abnormality in CKD 16 
 There is ↓ T3, normal r T3, low or normal T4,and the TSH 
may be  normal or rises in hypothyroidism. 
 
 Iodide excretion decreases in advanced kidney failure. The increase 
in iodide blocks thyroid hormone (Wolf -chaikoff effect) which leads to 
Hypothyroidism (Kidney International). 
 
 Decreased level T3 is due to decreased conversion of T4-T3, this is 
not associated with increased T4-rT3; this differentiates from other patients 
of chronic illness. 
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MATERIALS AND METHODS 
 
This study was conducted in 50 patients with chronic kidney disease 
and 50 normal people taken as controls. 
 
 All the patients in this study group were selected from those who 
were admitted to department of Internal Medicine, Govt. Annal Gandhi 
Memorial Govt  Hospital, attached to K.A.P.Viswanatham Govt Medical 
college, Trichy. 
 
Inclusion Criteria:  
1.  Patients between age group of 40 to 80 years with established 
chronic Kidney disease. 
2.  Patients who were on conservative treatment. 
3.  Established renal failure was ensured by radiological evidence. 
 
EXCLUSION CRITERIA 
1.  Patients with Acute renal failure, nephrotic syndrome. 
2.  Who are on drugs β blockers, statins and oral contraceptive pills. 
3.  Pregnant female patients. 
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STUDY DESIGN: Descriptive observational study 
Written consent is obtained from all the patients and controls 
 History regarding symptoms and duration of the kidney disease, 
hypertension, diabetes, smoking, alcoholism, drug intake and treatment 
were elicited. A detailed clinical examination was performed in all patients 
including Height and Weight, Blood Pressure, renal function tests, 
abdominal ultra sonogram and Electrocardiogram were done for all 
patients.  
 
After 12 hours of overnight fasting blood sample was taken for lipid 
profile from patients and controls and for TSH levels  from patients. 
 
The following tests are also performed:  
 Fasting blood glucose and post prandial (mg/dL) 
 Haemoglobin A1C, Serum albumin 
 24 Hrs urine proteins, urine P/Cr ratio and creatinine clearance 
Estimated Glomerular filtration rate (eGFR), as assessed by CKD-EPI 
 
32 
LABORATORY METHODS FOR ESTIMATING LIPIDS 
HDL-C Estimation: (Erba Mannheim - XL System packs) 
Methodology: 
The assay is based on a modified polyvinyl sulfonic acid (PVS) and 
polyethylene-glycol-methylether (PEGME) coupled classic precipitation 
method with the improvements in using optimized quantities of 
PVS/PEGME and selected detergents. LDL, VLDL and chylomicron (CM) 
react with PVS and PEGME and the reaction results in inaccessibility of 
LDL, VLDL and CM by cholesterol oxidase (CHOD) and cholesterol 
esterase (CHER).The enzymes selectively react with HDL to produce 
H2O2 which is detected through a Trinder reaction. Reagent1 (R1) 
contains PVS and PEGME and Reagent2 (R2) contains cholesterol esterase 
and cholesterol oxidase. 
 
  
HDL+LDL+VLDL+CM  
 
HDL + (DLD+VLDL+CM).PVS/PEGME 
HDL+CHOD+ CHER  Fatty acid + H2O2 
    Peroxidase 
 
2H2O2+4-AA+ TODB  Quenone+5H2O 
PVS
PEGME
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 EXPECTED VALUES: 
Adults male: 35.3 -79.5mg/dl 
Adults female: 42.0 -88.0 mg/dl 
 
Cholesterol estimation (Erba Mannheim - XL System packs) 
METHODOLOGY: 
This method is based on the Trinders methodology. 
 
PRINCIPLE: 
  CHE 
1. Cholesterol ester + H2O   Cholesterol +Fattyacids  
 
   CHO 
2. Cholesterol + O2   Cholest-4-en-3-one+H2O2 
 
  POD 
3. 2H2O2+4AAP+Phenol Quinoneimine dye + 4H2O 
 
CHE     : Cholesterol esterase 
CHO    : Cholesterol Oxidase 
4AAP   : 4-Aminoantipyrine 
POD    : Peroxide 
 Absorbance of Quinoneimine so formed is directly proportional to 
cholesterol concentration. 
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CALCULATION: 
 Cholesterol (mg/dl) = (Abs of Test/Abs of standard) * 
Concentration of std (mg/dl) 
Expected values: 
Adults < 200 mg/dl. 
 
TRIGLYCERIDE ESTIMATION (Erba Mannheim - XL  
METHODOLGY 
 The series of reactions involved in the assay system is as follows: 
   LPL 
Triglycerides + H2O  Glycerol + Free Fatty acids 
 
 GK 
Glycerol + ATP  Glycerol-3-Phosphate + ADP 
 
   GPO 
Glycerol-3-Phosphate + O2  DAP + H2O2 
 
 POD 
H2O2+ 4AAP+ADPS Quinoneimine dye + H2O 
 
 
1.  Triglycerides are enzymatically hydrolyzed by lipase to free acids 
and glycerol. 
2.  The glycerol is phosphorylated by adenosine triphosphate (ATP) 
with glycerol kinase (GK) to produce glycerol-3-phosphate and 
adenosine diphosphate (ATP). 
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3.  Glycerol-3-Phosphate is oxidized to dihydroxy-acetone phosphate 
(DAP) by glycerol phosphate oxidase producing hydrogen peroxide 
(H2O2). 
4.  In a Trinder type colour reaction catalyzed by peroxidase, the H2O2 
reacts with 4-aminoantipyrine (4AAP) and 4-Chlorophenol (3, 5 
ADPS)  to produce a red coloured dye .The absorbance of this dye is 
proportional to the concentration of triglycerides present in the 
sample. 
 
EXPECTED VALUES: 
Recommended Triglycerides levels for adults: 
Male     : 40-160 mg/dl 
Female: 35-135 mg/dl 
LDL was estimated by using Friedwald formula 
LDL = Total cholesterol - (HDL-C + TGL/5) 
 
LABORATORY METHODS FOR ESTIMATING TSH 
 This method is generally regarded as the most sensitive indicator 
available for the diagnosis of primary and secondary hypothyroidism 
Increase in serum concentrations of TSH is an early & sensitive indicator 
of thyroid reserve. 
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PRINCIPLE OF THE TEST: 
 The ERBA THYROKIT TSH kit is a solid phase enzyme-linked 
immunosorbent   assay (ELISA) based on the sandwich principle. 
 
 The microtiter wells are coated with a monoclonal (mouse) antibody 
directed towards a unique antigenic site of the TSH molecule. An aliquot 
of patient sample containing endogenous TSH is incubated in the coated 
well with enzyme conjugate, which is an unbound conjugate, is washed 
off. 
 
 The amount of bound peroxidase is proportional to the concentration 
of TSH in the sample. 
 
 Having added the substrate solution, the intensity of colour 
developed is proportional to the concentration of TSH in the patient 
sample. 
 
Normal range is from 0.3 to 4.0 mlU/L 
Sensitivity: 70.8% 
Specificity: 100% 
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Radiological imaging studies 
 Ultra sonogram showing reduced kidney size (<9cm) with altered 
cortico medullary differentiation was taken as radiological evidence of 
chronic kidney disease. 
 Electrocardiogram of all patients was studied in detail. 
 
In this study 
LDL > 130 mg/dl 
HDL < 40 mg/dl 
TGL > 160 mg/dl 
TC > 200 mg/dl were considered abnormal 
 
STATISTICAL METHODS 
Mean values were obtained for LDL, HDL, TGL & Total cholesterol 
separately. Then standard deviations were calculated for each category of 
observations for both study and control group.  Students T test was 
performed & T value was obtained. P value from t value was calculated.  
P value of <0.05 was considered significant. 
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RESULTS AND  OBSERVATIONS 
 
AGE DISTRIBUTION 
Age of the patients varied from 40 yrs to 75 yrs. Majority of patients 
fall in the age group between 46-55 years.  
 
AGE DISTRIBUTION IN PATIENTS 
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SEX DISTRIBUTION 
Males constitute 39(78%) and females constitute 11(22%) in this 
study 
 
 
PERSONAL HABITS 
In this study10 patients of the patients were smokers And  6  patients 
were alcoholics 
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RENAL PARAMETERS 
Lowest urea value found in these patients was 38 and the highest 
was 157mg/dl 
 Creatinine values ranged between 1.3 mg/dl to 13.7 mg/dl. 
 
GFR-EPI  Values 
 
GFR No. of patients 
<15ml 
 
11 
 
15-29ml 28  
30-59ml 11  
 
Correlation between GFR and sr.creatinine. 
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BLOOD PRESSURE READINGS 
Patients with blood pressure of more than 140/90 were considered 
hypertensives. Most patients (36 patients) were hypertensives at the time of 
presentation. Only 14 patients had blood pressure less than 140/90mmHg. 
DIABETIC STATUS It was found that 18patients were diabetic 
 
 
 
RADIOLOGICAL EXAMINATION 
Radiological examination was done by abdominal ultra sonogram. 
In 39 patients the kidney size was less than 9cm in one or both kidneys.  
 
ECG RESULTS 
Patient’s electrocardiograms were analysed. It was found that 17 
patients showed left ventricular hypertrophy. 16 patients showed ischemic 
changes. One patient had tall peaked T waves. 
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ECG CHANGES IN CKD PATIENTS (STUDY GROUP) 
Type of ECG changes Males Females Total 
LVH 15 2 17 ( 34 % ) 
Ischemic changes  12 4 16 (32%) 
 
CKD PATIENTS SHOWED THE FOLLOWING LIPID DISORDER 
Type of lipid Disorders Number of Patients 
Elevated Cholesterol 20 
Decreased HDL 40 
Elevated Triglycerides 31 
Increased LDL Cholesterol 12 
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LIPID PATTERN IN OUR STUDY  
HDL PATTERN 
Serum HDL values ranged between 23mg/dl to 46mg/dl.Patients 
showed abnormal HDL levels (<40 mg/dl) were 40.Its mean value was 
35.08 and standard deviation was 4.84. The P value is <0.01 Among the 
control groups, the lowest value of HDL was 36 mg/dl and the highest was 
58 mg/dl. Their mean was 46.96 and standard deviation was 5.59 .P value, 
<0.01 
 
 It showed that there was a significant reduction in HDL-C levels in 
patients with CKD than that of controls. 
 
LDL PATTERN 
Lowest value of LDL 52mg/dl and the highest value were189mg/dl. 
Abnormally high LDL levels (>130mg/dl) were found in 12 patients. Their 
mean value was 188.78 mg/dl and standard deviation was 5.680 and P 
value was < 0.01 significant. 
 
For controls lower value is 76mg/dl, highest value is126mg/dl their 
mean was 105.58 and standard deviation is 12.59 and P value was <0.01 
which is significant 
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TGL PATTERN 
TGL value in our study group ranged between  the minimum of 
73mg/dl and the maximum of 313mg/dl. TGL levels were abnormal in 31 
patients >160mg/dl).Mean and standard deviation of study group were 
165.04and 50.8 In controls, the lowest value is 70 and the highest is 
170mg/dl. The mean and standard deviation were 117.68 and 17.43. P 
value was significant (P < 0.01) in both the groups. 
 
TOTAL CHOLESTEROL 
Range of TC levels in study group was 120mg/dl to 280 mg/dl. 
Lowest value in control group was 143 and the highest value was 
220mg/dl. Total cholesterol was more than 200mg/dl in 20 patients. The 
mean values and standard deviations of study group were 188.78 and 
40.16. In the control group. The mean values and standard deviations of 
were 117.68 and 17.43 P value was (P<0.01) significant in both the groups. 
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GRAPHS (STUDY GROUP) 
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CORRELATION BETWEEN LIPID FRACTIONS AND GFR  IN 
PATIENTS 
LIPIDS eGFR<15ml 15-29ml 30-59ml 
TC ↑ 5 12 3 
TGL ↑ 5 19 7 
HDL ↓ 8 23 9 
LDL ↑ 3 6 2 
 
TSH  Level  
  TSH level increased in 16 patients in this study. 
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DISCUSSION 
 
In our study, most common lipid abnormalities found were Low 
HDL levels and Hypertriglyceridemia. 
  
DECREASED HIGH DENSITY LIPOPROTEIN LEVELS 
The low HDL levels in patients with chronic kidney disease in our 
study were consistent with Diana M Lee LG et al 43 who studied the lipid 
profile in CRF patients. 
 
This low HDL cholesterol levels was also an independent risk factor 
for the development of CKD in the Framingham off spring study. Several 
mechanisms may underlie these reductions in HDL cholesterol levels, 
which is usually an indication of impaired reverse cholesterol transport. 
Apo AI, which is the activator of lecithin cholesterol acyltransferase 
(LACT), is reduced in CKD due to down regulation of hepatic Apo AI 
genes leads to decline in the activity of LACT, which causes reduced 
cholesterol esterification and impairment of HDL maturation. The activity 
of LACT is consistently diminished in CKD, so there is decrease in HDL 
levels. 44  
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In MDRD study 55 low HDL levels in CKD patients were one of the 
independent risk factor for progression of kidney disease.  In our study the 
mean value was significantly less than the age matched healthy controls. 
 
ELEVATED TRIGLYCERIDES 
Triglyceride levels were significantly elevated in our study than 
control group. Abnormal triglyceride values were found in 31 of patients in 
our study. The present study demonstrates that CRF is commonly 
accompanied by lipid abnormality in the form of hypertriglyceridemia. 
This is similar to the observations made in Western studies and recent 
Indian studies45,46,47,48 by Gupta DK,Das BS and Bagdae J. Elevated 
triglyceride levels are due to impaired activity lipoprotein lipase  (LPL)49  
and direct inhibitory effect of various uremic ‘toxins’ on the enzymes 
involved in lipid metabolism50 represent the most important 
pathophysiological mechanisms underlying the development of 
hypertriglyceridemia in renal failure. 
 
 Chan MK et al 48 also found hypertriglyceridemia was the major 
abnormality in their studies. Hypertriglyceridemia represents an early 
feature of renal failure. 
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ELEVATED LOW DENSITY LIPOPROTEIN 
LDL was significantly elevated than that of controls in our study. 
We found that 12 of patients showed elevated LDL levels. Most studies 
find that Uremic Patients usually have normal or slightly reduced 
concentrations of LDL-C levels and they exhibit important disturbance in 
the density distribution of LDL sub fraction that is characterized by a 
predominance of small dense LDL particles.51  
 
In the present study we find significantly high levels of LDL 
cholesterol in the group with GFR15-29ml.  
 
TOTAL CHOLESTEROL 
Total cholesterol levels were elevated in 20 patients in our study 
group  heavy proteinuria alone or in combination with chronic renal 
insufficiency results in acquired LDL receptor deficiency, which plays a 
central role in the genesis of the associated hypercholesterolemia. 53  
 
Correlation Studies: 
It was found that abnormal serum triglycerides, TC, HDL, were 
found to be increased significantly in the group of eGFR between15-29ml  
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ECG changes: 
Out of 50 patients, 17 (34%)of patients showed changes suggestive 
of LVH and   16 ( 32 %) of patients showed ischemic changes. 
 
The risk of dying of cardiac complications is 65 times higher in 
dialysis patients between 45-54 years and 500 times higher than the 
general population. The risk factors which are responsible for increased 
morbidity and mortality were hypertension, DM, high LDL, low HDL and 
smoking.  
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CONCLUSION 
 
1.  HDL-C levels were lower and triglycerides, total cholesterol and 
TGL levels were higher in the study group compared to controls.  
 2.  There is a statistically significant increase in serum triglycerides 
level in patients with CKD stage 3,4 and 5. 
4.  Predominant lipid abnormalities were reduced HDL-C levels and 
elevated TGL.  
5.  There was a negative correlation exists between serum HDL-C level 
and GFR levels which was statistically significant. 
6..  Significant number of patients showing ECG changes of left 
ventricular hypertrophy 34 %and ischemic changes 32%. 
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LIMITATIONS OF THE STUDY 
 
1.  Smoking, alcoholism and diabetics may alter the lipid pattern in the 
body. Their influences in the study group also have to be considered. 
2.  Since we had not analysed the echocardiogram of the patients, the 
real scenario of ischemia in CKD patients was not known. 
3 . We had not estimated the lipid abnormalities in patients who 
underwent dialytic treatment or renal transplantation. 
 
 ACRONYMS 
 
Apo - Apolipoprotein 
BP - Blood Pressure 
CGN-chronic glomerulonephritis 
CIN-chronic interstitial nephritis 
CKD - Chronic Kidney Disease 
CVD - Cardio Vascular Disease 
DM - Diabetes Mellitus 
ECG - Electro Cardiogram 
ESRD - End Stage Renal Disease 
GFR - Glomerular Filteration Rate 
HDL-C - High Density Lipoprotein Cholesterol 
HTN - Hypertension 
ID No - Patient identification Number 
K+ - Potassium 
K/DOQI - Kidney Disease Outcome Quality Initiative 
LCAT - Lecithin Cholesterol Acyl Transferase 
LDL-C - Low Density Lipoprotein Cholesterol 
LK - Left Kidney 
LPL - Lipoprotein Lipase 
LVH - Left Ventricular Hypertrophy 
MDRD study - Modification of Diet in Renal Disease study 
 Na+ - Sodium 
PD-peritoneal dialysis 
PMP - Per Million Population 
PTH-parathyroid hormone 
RK - Right Kidney 
Sd LDL - Small Dense Low Density Lipoprotein 
TC - Total Cholesterol 
TGL/TG - Triglycerides 
USG - Ultra Sonogram 
 
 BIBILOGRAPHY 
 
1.  Sarnak MJ, Levey AS, Schoolwerth AC,Coresh J, Culleton B, 
Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, 
ParfreyP, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney 
disease as a risk factor for development of cardiovascular disease: a 
statement from the American Heart Association Councils on Kidney 
in Cardiovascular Disease,High Blood Pressure Research, Clinical 
Cardiology, and Epidemiology and Prevention. Circulation 2003; 
108: 2154–2169 
2.  Hallan SI, Coresh J, Astor BC, Asberg A,Powe NR, Romundstad S, 
Hallan HA, Lydersen S, Holmen J: International comparison of the 
relationship of chronic kidney disease prevalence and ESRD risk. J 
Am Soc Nephrol2006; 17: 2275–2284 
3.  Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of 
cardiovascular disease in chronic renal disease. Am J Kidney Dis 
1998; 32:S112–S119. 
 4.  Go AS, Chertow GM, Fan D, McCulloch CE,Hsu CY: Chronic 
kidney disease and the risks of death, cardiovascular events, and 
hospitalization. N Engl J Med 2004; 351: 1296–1305. 
5. Dyslipidemia in patients with chronic renal failure and in renal 
transplant patients. B.Shah,S.Nair,RASirsat,TFAshavaid, K.Nair 
Nephrology Section, PD Hinduja National Hospital's Research 
Centre, Mahim, Bombay 
 6.  Study of lipid profile and oxidative stress in chronic renal 
failure. Sumathi M.E., Manjunath M Tembad, Jayaprakash murthy 
D.S., Preethi B.P. Biomedical Research 2010; 21 (4): 451-456 
7.  Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk 
Combination. VeeraishChauhan,MD and Megha vaid MPH 
Postgraduate Medicine: Volume: 121 No.6 DOI: 
10.3810/pgm.2009.11.2077 
8.  NKF-KDOQI guidelinesNKF KDOQI GUIDELINES  
9.  Chronic kidney disease in India – a hidden epidemicIndian J Med 
Res 126, July 2007, pp 6-9 
10.  Chronic Kidney Disease in India: Challenges and Solutions 
S.K. Agarwal, R.K. Srivastava,Nephron Clin Pract 2009;111:c197-
c203 (DOI: 10.1159/000199460 
 11. Incidence of chronic kidney disease in India Suresh Chandra Dash 
and Sanjay  KAgarwal Nephrol. Dial. Transplant. (January 2006) 
21 (1): 232-233. 
12. HARRISON’S PRINCIPLES OF INTERNAL MEDICINE 18th 
edition 
13.  The National Kidney Foundation K/DOQI Clinical Practice 
Guidelines for Estimation of Glomerular Filtration Rate 
14.  Lewington S, Whitlock G, Clarke R, SherlikerP, Emberson J, Halsey 
J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular 
mortality by age, sex, and blood pressure: a meta-analysis of 
 individual data from 61 prospective studies with 55,000 vascular 
deaths. Lancet 2007; 370: 1829–1839 
15.  Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III   
16. Brennar and Rocks,THE KIDNEY,eighth edition 2006. 
17.  Muntner.P,cersh.j,smith JC,Plasmalipids and risk of developing 
renal dysfunction.Kidney Int.50(1) 293-301,2000 
18. Attman PQ,AlanporiCP,SamuelssonO,Lipoprotein abnormality as a 
risk factor for progressive non diabetic renal disease,Kidney Int.56 
S14 –S17,1999) 
19. Toto RD,Vega G,Grudy SM cholesterol management in patients 
with CKD. Therapy in Nephrology and HT Lippincott Williams and 
Wilkis PP 631-639 
 20.  Vaziri ND: Dyslipidemia of chronic renal failure: The nature, 
mechanisms and potential consequences. Am J Physiol Renal 
Physiol 2006; 290: 262–272.] 
21  Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase 
expression in experimental chronic renal failure. Kidney Int 1996; 
50: 1928–1935. 
22  Vaziri ND, Liang K, Parks JS: Down-regulation of hepatic 
lecithin:cholesterol acyltransferase gene expression in chronic renal 
failure. Kidney Int 2001; 59: 2192 
 23  Mori Y, Hirano T, Nagashima M, Shiraishi Y,Fukui T, Adachi M: 
Decreased peroxisome proliferator-activated receptor alpha gene 
expression is associated with dyslipidemia in a rat model of chronic 
renal failure. Metabolism 2007; 56: 1714–1718. 
24.  Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, 
Alaupovic P: Lipoprotein particle abnormalities and the impaired 
lipolysis in renal insufficiency. Kidney Int 2002; 61: 209–218. 
25  Cheung AK, Parker CJ, Ren K, Iverius PH: Increased lipase 
inhibition in uremia: identification of pre-beta-HDL as a major 
inhibitor  in normal and uremic plasma. Kidney Int 1996; 49: 1360–
1371. 
26.  Lipid Disorders and Their Relevance to Outcomes in Chronic 
Kidney Disease. Nosratola D. Vaziri a Keith Norris b a Division of 
Nephrology and Hypertension, University of California Irvine, 
Irvine, Calif., and b Department of Internal Medicine, Charles Drew 
University, Los Angeles, Calif., USABlood Purif 2011;31:189–196. 
DOI: 10.1159/000321845] Dyslipidemia of CKD Blood Purif 
2011;31:189–196 191 
27  Vaziri ND, Deng G, Liang K: Hepatic HDLreceptor, SR-B1 and 
Apo A-I expression inchronic renal failure. Nephrol Dial 
Transplant1999; 14: 1462–1466 
28  Shoji T, Nishizawa Y, Nishitani H, BillheimerJT, Sturley SL: 
Impaired metabolism of high density lipoprotein in uremic patients. 
Kidney Int 1992; 41: 1653–1661. 
 29  Liang K, Kim C, Vaziri ND: HMG-CoA reductase inhibition 
reverses LCAT and LDL receptor deficiencies and improves HDL in 
rats with chronic renal failure. Am J Physiol Renal Physiol 2005; 
288:F539–F544. 
30  Vaziri ND, Liang K, Parks JS: Downregulation of 
lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. 
Kidney Int 2001; 59: 2192–2196. 
31. Vaziri ND and Liang K. Downregulation of hepatic LDL receptor 
expression in experimental nephrosis. Kidney Int 50: 887–893, 1996 
32. Vaziri ND, Sato T, and Liang K. Molecular mechanism of altered 
cholesterol metabolism in focal glomerulosclerosis. Kidney Int 63: 
1756–1763, 2003. 
33.  Kronenberg F, Kuen E, Ritz E, et.al.: Lipoprotein(a) serum 
concentrations and apolipoprotein(a) phenotypes in mild and 
moderate renal failure. J Am Soc Nephrol 11 : 105 -115, 2000  
34.   Rutkowski B, Chmielewski M. Mechanisms of lipid disturbances in 
chronic renal failure. Nephrology, hypertension, dialysis, 
transplantation. Budapest: Hungarian Kidney Foundation; 2005:467-
476. ) 
35.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and 
potential consequences . N. D. Vaziri AJP - Renal Physiol February 
2006 vol. 290 no. 2 F262-F272. AJP - Renal Physiol February 
2006 vol. 290 no. 2 F262-F272  
 36. Magil AB. Interstitial foam cells and oxidized lipoprotein in human 
glomerular disease. Mod Pathol 12: 33–40, 1999.).  
37. Moorhead JF, Wheeler DC, and Varghese Z. Glomerular structures 
and lipids in progressive renal disease. Am J Med 87: 12N–20N, 
1989., 
38. Wheeler DC and Chana RS. Interactions between lipoproteins, 
glomerular cells and matrix. Miner Electrolyte Metab 19: 149–164, 
1993.) 
38. Sharma BK, Jindal SK, Rana DS. Absence of hypedipidemia in 
patients of chronic renal failure in Chandigarh. Indian J Med Res 
1980; 72:461 464.   
39. Kunde AA, Mani MK, Kuruvilla KC. Lipid abnormality in chronic 
renal failure and haemodialysis. J Assoc Physicians India [abstract] 
1977; 25:1013 
40. Gupta DK. Hypedipidemia in patents of chronic renal failure. 
Bombay Hospital J 1991; 33:45 50 
41. Das BS, Mishra SK, Rao DVP. Serum lipids in chronic renal failure. 
J Assoc Physicians India 1984; 32:1019 1021. 
42. Alterations of Lipid Metabolism in Chronic Nephropathies: 
Mechanisms, Diagnosis and Treatment Antonio Lacquaniti Davide 
Bolignan .o Valentina Donato Caterina Bono Maria Rosaria Fazio 
Michele Buemi Section of Nephrology, Department of Internal 
Medicine University of Messina, Messina, Italy.  Kidney Blood 
Press Res 2010;33:100–110 DOI: 10.1159/000302712 
 43.  DIANA M.LEE et al:Lipoprotein particle abnormalities and the 
impaired lipolysis in renal insufficiency,kidney international, 
vol.61,2002,pp209-218 
44.  Vaziri ND, Liang K, Parks JS. Down regulation of hepatic lecithin: 
cholesterol acyltransferase gene expression in chronic renal failure. 
Kidney Int 2001; 59: 2192-6.. 
45. Gupta DK. Hypedipidemia in patents of chronic renal failure. 
Bombay Hospital J 1991; 33:45 50.  
 46. Das BS, Mishra SK, Rao DVP. Serum lipids in chronic renal failure. 
J Assoc Physicians India 1984; 32:1019 1021.  
 47. Bagdade J, Casaretto A. Effect of chronic uremia, haemodialysis and 
renal transplantation on plasma lipids and lipoproteins. J Clin 
Invest1976;87:3741 
48. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in'uremia. 
Kidney Int 1981; 19:625  
 49. Kes P. Lipid abnormalities in CRF, nephritic syndrome and dialysis. 
Acta Med Crotica 2001; 55(4-5): 177-86 
50. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase 
inhibition in uremia: I dentification of pre-beta HDL as a major 
inhibitor in normal and uremic plasma. Kidney Int 1996; 49 (5): 
1360-7)  
51.  Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-
density lipoprotein subfraction profiles in chronic renal failure. 
Nephrol Dial Transplant. 1998;13:2281–7.  
 52.  Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard 
CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: 
origin and extent of small dense low-density lipoprotein formation. 
Am J Kidney Dis. 2000;35:852–62. 
 53,  Vaziri ND and Liang K. Downregulation of hepatic LDL receptor 
expression in experimental nephrosis. Kidney Int 50: 887–893, 1996 
54. A M Rao, A R Bitla, E P Reddy, V Sivakumar* and P V L N 
Srinivasa RaoA M Rao, A R Bitla . LIPID ABNORMALITIES, 
LIPOPROTEIN (a) AND APOPROTEIN PATTERN IN NON-
DIALYZED PATIENTS WITH CHRONIC KIDNEY 
DISEASEIndian Journal of Clinical Biochemistry, 2010 / 25 (1) 47-
50 
55.  LAWRENCE G.HUNSICKER et al: Predictors of the progression of 
renal disease in the modification of diet in renal disease study, 
Kidney international,vol 51,1997,pp 1908-1919. 
 
 
 
Sl
 
N
u
m
b
e
r
N
a
m
e
A
g
e
S
e
x
 
I
D
 
N
o
H
e
i
g
h
t
 
c
m
W
e
i
g
h
t
 
k
g
S
m
o
k
i
n
g
A
l
c
o
l
h
o
l
i
s
m
B
P
D
M
H
T
F
B
S
m
g
%
P
P
B
S
m
g
%
H
b
A
1
c
%
S
r
.
a
l
b
 
g
/
d
l
U
r
e
a
m
g
%
S
r
.
c
r
e
a
t
i
n
i
n
e
m
g
%
 
N
a
 
m
e
q
/
l
K
 
m
e
q
/
l
2
4
h
r
s
 
U
.
p
r
o
 
m
g
u
r
i
n
e
 
p
/
c
r
 
r
a
t
i
o
c
r
.
c
l
e
a
 
m
l
/
m
t
U
r
i
n
e
-
 
a
l
b
T
C
T
G
L
L
D
L
H
D
L
T
S
H
e
G
F
R
ECG
U
S
G
 
R
K
 
s
i
z
e
U
S
G
 
L
k
 
s
i
z
e
1 Arumugam 50 M 512038 170 65 N N 150/90 N Y 94 124 3.4 3.4 64 3 137 4 450 1.2 30 nil 220 170 124 46 2.3 23 LVH 7.4 7.4
2 Abdul Nazeer 47 M 86118 145 50 N N 140/80 N Y 76 120 3.1 4.1 47 1.9 141 4 397 0.9 35 nil 280 301 189 31 10 41 N 8 9.2
3 Antony 68 M 35122 160 55 N Y 150/90 N Y 106 126 3.7 3.2 144 13.7 136 4 300 1.2 20 nil 130 120 70 36 3.4 3 N 3.3 4.3
4 Ammasi 67 M 32165 150 50 N Y 180/100 N Y 117 263 2.9 3.5 68 3.2 131 5 350 1.1 14.6  + 215 161 127 41 11.4 19 N 8.3 8
5 Andi 65 M 34752 154 51 N N 140/90 N Y 96 127 3.6 3.3 60 3 137 4 340 1.4 18  + 204 200 120 36 2.5 21 N 8.3 8
6 Bala Sundaram 51 M 36625 160 60 N N 140/80 Y Y 126 240 4.5 3.4 65 2.7 142 45 250 0.9 23 nil 207 180 120 36 2.5 26 LVH 10.4 9.6
7 Kandasamy 55 M 267109 160 60 N N 160/80 Y Y 150 263 4.8 3.2 48 1.4 136 4 240 0.8 48 nil 160 165 109 30 1.6 56 LVH 10.2 11.1
8 kadhar moideen 50 M 15740 160 65 N N 170/100 N Y 91 114 3.2 3.5 52 1.5 132 4 103 0.13 35 nil 175 103 119 46 1.8 54 N 8.2 9.8
9 Kamaraj 48 M 42747 150 45 Y N 140/90 N Y 80 117 3.2 3.4 58 2.8 135 4 290 1.1 21 nil 174 181 107 33 10.4 24.8 N 7.5 7.5
10 Karuppiah 49 M 34760 153 50 N N 160/90 Y Y 165 260 3.5 3.8 72 4.2 135 4 249 1.6 13  + 130 95 89 46 5.2 16 T↓L2,aVL,V5-V6 8 7.5
11 Kunju Pillai 65 M 39478 165 60 N N 160/80 N Y 94 194 3.8 3.4 76 3.2 138 3 500 2 15  + 147 179 82 30 0.9 19 T↓V5-V6 7.2 7.8
12 Krishnan 47 M 345671 160 50 Y N 160/90 Y Y 160 274 6.5 3 67 3.5 139 4 400 1.3 20  + 165 194 140 34 2.1 20 LVH 8.7 8.1
13 Marutha muthu 40 M 31754 150 55 N N 160/90 N Y 92 124 3.4 3.4 104 8.1 135 42 300 0.8 10 nil 204 93 103 23 3.3 7 LVH 6.4 6.2
14 Murugan 70 M 23011 160 58 N N 170/100 N Y 83 142 3.2 4 64 3.2 139 5 280 0.7 17 nil 256 258 170 35 0.8 19 T↓V1-V6 8.2 8.3
15 Muthusamy 70 M 37654 150 50 N N 140/80 N Y 95 116 3.1 3.4 157 9.6 130 3 400 1.2 4  + 168 73 121 32 4.8 5 T↓L1,aVL,V5-V6 5.6 4.8
16 Natesan 70 M 33226 165 55 N Y 100/60 Y Y 94 120 2.1 2.7 84 2.8 125 5 192 0.9 7 nil 143 169 72 38 5.5 22 LVH 7.2 7
17 palanisamy 46 M 235107 160 57 N N 110/80 N N 81 117 3.3 3.2 60 3 136 4 374 0.7 25 nil 231 189 120 36 5.1 24 N 8.3 8.2
18 Paramasivam 52 M 1107 163 60 N N 130/80 N N 96 130 3.4 3.3 58 2.6 138 4 126 0.35 20 nil 187 173 117 32 3.2 26 T↓L2,L3,aVL,V2-V3 8 7.8
19 Raju 64 M 14411 165 60 N N 160/100 N Y 102 127 3.1 4.2 59 2.7 140 4 149 0.3 24 nil 168 128 107 36 0.6 24 T↓V5-V6 8.2 8.8
20 Ramraj 42 M 245178 160 58 Y N 150/90 N Y 86 112 3 3.9 82 3.8 132 4 725 2.5 24  ++ 135 163 76 27 2.8 18 N 8.2 8
21 Rayappan 70 M 38451 154 50 N N 180/80 N Y 60 110 3.2 3.4 42 1.5 140 4 200 0.7 40 nil 170 189 95 38 9 46 LVH 9 8.8
22 Rajalingam 65 M 34768 152 60 N N 170/80 N N 84 120 3.6 3.7 38 1.3 140 4 300 0.9 45  + 196 180 120 36 2 57 N 8.7 8.4
23 Rengasamy 55 M 47247 156 57 Y Y 150/90 N N 162 264 4.3 3.9 54 1.9 138 4 252 0.9 38 nil 162 176 92 35 1.7 39 T↓V1-V3 7.1 7.4
24 Rengasamy 55 M 50061 154 58 N N 160/80 N N 113 147 4.2 4.1 60 1.7 135 4 260 1.2 42 nil 155 85 106 32 5.1 44 N 8.2 8
25 Rengasamy 51 M 34765 154 56 N N 140/90 N N 104 148 2.7 4.8 67 5.1 137 4 720 2.9 30  ++ 164 97 117 28 2.1 12 N 7.6 7.3
26 Sakthivel 40 M 17094 155 56 Y N 150/100 N N 130 262 2.8 3.6 60 3.2 140 5 222 0.8 40  + 180 135 117 36 1.8 23 N 9.4 10
27 Sakthivel 42 M 1006 158 58 N N 150/90 N N 126 262 2.8 3.6 60 3.2 136 4 222 0.8 40 nil 180 135 117 36 2.2 23 N 8.4 8.1
28 Sasikumar 44 M 38807 154 54 N N 180/100 N Y 150 190 4.6 3.1 125 4.5 131 4 261 0.86 23 nil 191 118 135 33 7.7 15 LVH 9 8
29 Savariayar 50 M 69238 158 56 N N 100/80 N Y 102 126 3.1 3.8 40 1.5 137 5 391 0.5 42  + 147 129 88 34 1.3 57 T↓V1-V6 9 8
30 Selvaraj 42 M 29750 156 60 N N 160/90 N Y 92 0.5 2.7 3.6 95 4.1 129 5 270 0.9 18 nil 155 110 106 27 0.5 17 N 7.6 7.8
31 Sivaanandham 58 M 36025 160 50 N N 150/90 Y Y 143 231 4.8 3.2 60 2.8 134 4 600 1.2 20 nil 231 209 178 45 3.5 24 ST dep.L2,L3,aVF,T↓aVL 9 8.5
32 Syed Jaffer 45 M 44410 162 60 Y Y 160/100 N Y 86 127 3.2 3.4 58 3 138 4 400 1.1 22.5  + 240 200 168 38 3.7 24 LVH with strain 7.8 9.1
33 Thangarajan 40 M 36721 168 61 N N 150/100 N Y 90 124 3.1 3.4 62 3.1 136 4 270 0.8 25 nil 168 174 108 34 5.1 24 LVH,T↓L1,,aVL,V5-V6 8.1 8.4
34 Vellayan 50 M 38742 152 50 Y N 120/70 N Y 87 140 3.4 3.3 52 2.8 135 4 180 0.4 24 nil 180 194 117 34 3 25 T↓,LVH,V1-V6 8.8 8.5
35 Yusuf 71 M 37942 160 60 N N 150/100 N Y 96 130 4.2 3.4 55 2 141 5 300 0.9 34 nil 220 258 127 42 1 33 SVT,LVH,RAE 9 8.6
36 Vadivel 45 M 32907 158 54 Y N 160/100 N Y 120 140 2.7 2.6 48 1.6 129 5 152 0.4 26 nil 158 138 97 34 2.1 51 LVH 7.6 7
37 Sakthivel 40 M 345678 164 58 N N 180/100 N Y 96 126 3.8 3.6 60 3.4 136 4 240 0.7 25 nil 216 190 124 36 5 21 LVH 7.8 7.6
38 Arockiamary 45 F 35507 150 45 N N 150/90 N Y 96 130 3.8 3.6 101 6.1 140 4 197 0.32 8.5  + 205 179 147 28 8.8 8 T↓L1,L2,aVL,V4-V6 8.3 8
39 Krishnammal 54 F 32230 145 45 N N 130/80 Y Y 126 263 6.6 2.9 126 4.2 136 4 335 1.2 3.5  + 128 103 52 45 3.1 11 N 10 10.1
40 Maria pusham 47 F 29212 150 50 N N 160/100 N Y 81 114 3.7 3.3 54 3.2 134 4 354 0.6 18 nil 264 103 119 30 1 16 T↓V1-V3 8 7.8
41 Muthulakshmi 48 F 38583 154 56 N N 140/90 Y Y 137 337 6.7 3 69 3 140 4 250 0.6 20 nil 152 150 80 44 3.8 18 N 9.6 9.8
42 Periammal 69 F 345832 145 65 N N 150/90 N N 92 119 3.1 3.5 82 2.7 128 5 198 9 12.8  ++ 267 313 161 38 3.2 17 LVH 8.3 9.1
43 Ponnammal 47 F 6764 158 67 N N 130/80 N N 82 124 3.5 3.4 65 2 134 4 315 1.4 17  + 210 179 127 34 3.3 29 LVH 8 8
44 Ranjitha mary 70 F 38984 150 45 N N 160/80 N N 103 278 3.2 3.6 62 2.2 135 5 128 4.1 35  nil 173 113 123 28 1.4 22 N 7.8 8
45 Sarabee 47 F 385399 150 45 N N 120/80 N N 185 270 5.6 3.3 158 9.8 128 4 200 0.8 13  nil 120 151 56 34 2 4 N 8.7 10.4
46 Sarojini ammal 55 F 38502 145 50 N N 140/80 N Yes 117 132 3.2 3.3 81 3.5 140 4 450 1.6 10  + 212 182 153 33 3.3 14 N 7.8 8
47 Thangammal 55 F 39299 150 48 N N 170/90 N Yes 178 290 5.8 3.2 90 5 140 4 128 5.1 13  nil 172 192 98 36 7.5 9 T↓L2,aVF,V4-V6 8 8.2
48 Chellammal 70 F 18518 145 46 N N 150/90 N Yes 109 127 3.2 3.2 45 1.5 136 3 587 1.3 25.3  + 260 178 184 41 1.5 35 St dep.V1-V3,T↓V1-V6 7.6 7.7
49 ananda gopal 55 M 55116 150 50 Y N 120/80 N yes 87 117 3.1 3.3 88 4.5 135 4 350 1.2 16  + 235 187 135 35 5.1 14 LVH 8.4 7.9
50 marimuthu 50 M 37284 160 55 Y Y 140/100 Y N 146 265 6.2 3.4 123 7.4 118 5 400 1.5 6  + 229 200 147 42 7 8 tall T waves 11.4 11.3
